Abstract
In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.
Keywords: Antibody Directed Enzyme Prodrug Therapy, ADEPT, Anticancer Therapy, Alkaline Phosphatase, Amino Peptidases, Aryl Sulfatase, Carboxylesterase, Carboxypeptidase A, Carboxypeptidase G2 (CpG2), Cytosine Deaminase
Mini-Reviews in Medicinal Chemistry
Title: Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Related Approaches for Anticancer Therapy
Volume: 1 Issue: 4
Author(s): M. Jung
Affiliation:
Keywords: Antibody Directed Enzyme Prodrug Therapy, ADEPT, Anticancer Therapy, Alkaline Phosphatase, Amino Peptidases, Aryl Sulfatase, Carboxylesterase, Carboxypeptidase A, Carboxypeptidase G2 (CpG2), Cytosine Deaminase
Abstract: In antibody directed enzyme prodrug therapy (ADEPT) an antibody bound enzyme is targeted to tumor cells. This allows for selective activation of a nontoxic prodrug to a cytotoxic agent at the tumor site for cancer therapy. Site-selective prodrug activation results in reduced side effects in remote tissue. This article reviews ADEPT with emphasis on the chemical viewpoint and recent developments.
Export Options
About this article
Cite this article as:
Jung M., Antibody Directed Enzyme Prodrug Therapy (ADEPT) and Related Approaches for Anticancer Therapy, Mini-Reviews in Medicinal Chemistry 2001; 1 (4) . https://dx.doi.org/10.2174/1389557013406747
DOI https://dx.doi.org/10.2174/1389557013406747 |
Print ISSN 1389-5575 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5607 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Review of and Perspectives on the Toxicology of Graphene-based Materials
Current Drug Metabolism MicroRNA Regulation of TRAIL in Renal Carcinoma: Tiny Juggernauts at Work
Current Molecular Pharmacology The Promise of miRNA Replacement Therapy for Hepatocellular Carcinoma
Current Gene Therapy A Common Molecular Motif Characterizes Extracellular Allosteric Enhancers of GPCR Aminergic Receptors and Suggests Enhancer Mechanism of Action
Current Medicinal Chemistry Design of New Improved Curcumin Derivatives to Multi-targets of Cancer and Inflammation
Current Drug Targets Plant Cells as Pharmaceutical Factories
Current Pharmaceutical Design Polymer Membrane and Cell Models for Drug Discovery
Combinatorial Chemistry & High Throughput Screening Tumor-Receptor Imaging in Breast Cancer: A Tool for Patient Selection and Response Monitoring
Current Molecular Medicine Receptor Fragments: Intracellular Signaling and Novel Therapeutic Targets
Current Hypertension Reviews The Coordinated Role of CYP450 Enzymes and P-gp in Determining Cancer Resistance to Chemotherapy
Current Drug Metabolism Clinical Experience with Antiangiogenic Therapy in Leukemia
Current Cancer Drug Targets Near-infrared Light Activatable Multimodal Gold Nanostructures Platform: An Emerging Paradigm for Cancer Therapy
Current Cancer Drug Targets Non-histone Methylation of SET7/9 and its Biological Functions
Recent Patents on Anti-Cancer Drug Discovery Genetic and Epigenetic Heterogeneity in Cancer: The Ultimate Challenge for Drug Therapy
Current Drug Targets Natural Product-Inspired Synthesis of Thiazolidine and Thiazolidinone Compounds and their Anticancer Activities
Current Pharmaceutical Design High Specificity in Response of the Sodium-Dependent Multivitamin Transporter to Derivatives of Pantothenic Acid
Current Topics in Medicinal Chemistry Receptor Tyrosine Kinases as Therapeutic Targets the Model of the MET Oncogene
Current Drug Targets Effect of Canagliflozin, an SGLT2 Inhibitor, in Comparison with Atorvastatin on Dexamethasone-Induced Hepatic Steatosis in Albino Rats
Current Drug Therapy EGFR(S) Inhibitors in the Treatment of Gastro-Intestinal Cancers: Whats New?
Current Drug Targets NOTCH Signaling as a Novel Cancer Therapeutic Target
Current Cancer Drug Targets